Tempus AI (NASDAQ:TEM) CFO Sells 7,079 Shares of Company Stock

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CFO James Rogers sold 7,079 shares of the firm’s stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $63.02, for a total value of $446,118.58. Following the completion of the sale, the chief financial officer directly owned 98,945 shares of the company’s stock, valued at $6,235,513.90. This represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Price Performance

TEM stock traded down $4.01 on Thursday, reaching $59.61. 5,290,938 shares of the company’s stock were exchanged, compared to its average volume of 6,229,094. The stock has a fifty day moving average of $72.87 and a 200-day moving average of $57.56. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $89.09. The firm has a market cap of $10.87 billion, a PE ratio of -56.24 and a beta of 3.61. The company has a quick ratio of 2.48, a current ratio of 2.61 and a debt-to-equity ratio of 2.70.

Tempus AI (NASDAQ:TEM – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The firm had revenue of $411.54 million during the quarter, compared to analysts’ expectations of $409.39 million. During the same quarter in the prior year, the business posted ($0.46) earnings per share. Tempus AI’s revenue was up 23.1% compared to the same quarter last year. As a group, equities analysts predict that Tempus AI, Inc. will post -1.20 EPS for the current fiscal year.

Institutional Trading of Tempus AI

Institutional investors have recently bought and sold shares of the company. V Square Quantitative Management LLC acquired a new stake in Tempus AI in the third quarter valued at $27,000. EMC Capital Management purchased a new position in shares of Tempus AI in the second quarter valued at $29,000. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Tempus AI during the 3rd quarter worth $33,000. Ulland Investment Advisors LLC acquired a new position in shares of Tempus AI during the 3rd quarter worth $41,000. Finally, Heritage Family Offices LLP acquired a new position in shares of Tempus AI during the 3rd quarter worth $45,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Tempus AI

Investors following TEM have been watching these headlines:

  • Positive Sentiment: Tempus will present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium. The research exposure could showcase its oncology data and precision-medicine capabilities, though the headline does not disclose results or commercial impact. Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium
  • Positive Sentiment: Tempus and AstraZeneca extended their strategic services agreement through a fifth amendment. The expanded relationship may support Tempus’s data and services business and validates its capabilities with a major pharmaceutical partner; the supplied summaries do not specify the financial terms. Tempus AI and AstraZeneca Extend Strategic Services Agreement
  • Positive Sentiment: A recent investor-focused article cites data agreements expected to generate $193 million over five years and oncology pricing changes expected to add $80 million in average selling price during 2027. These figures offer potential revenue support, although they depend on execution and timing. Tempus AI: 3 Key Takeaways for Long-Term Investors

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on TEM shares. BTIG Research increased their price target on shares of Tempus AI from $80.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. HC Wainwright reissued a “buy” rating and set a $85.00 price objective on shares of Tempus AI in a report on Thursday. Robert W. Baird boosted their price objective on shares of Tempus AI from $85.00 to $92.00 and gave the stock an “outperform” rating in a report on Tuesday, November 3rd. UBS Group started coverage on shares of Tempus AI in a research report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price on the stock. Finally, Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. Eleven investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $79.37.

Read Our Latest Stock Report on Tempus AI

Tempus AI Company Profile

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

See Also

Insider Buying and Selling by Quarter for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.